Pharmacological Repositioning of Thiocolchicoside: Antibacterial Evaluation In vitro

Pharmacological repositioning has been increasingly praised as a viable, low-cost and rapid alternative for the development of a new therapy for clinical application, such as cases of bacterial resistance. Therefore, the present study aimed to investigate the antibacterial action of the myorelaxant thiocolchicoside. For this, an in vitro experimental study was developed using the bacterial strains Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Proteus mirabilis ATCC 25933 and Pseudomonas aeruginosa ATCC 27853, and the protocols: antibacterial activity screening, Minimum Inhibitory Concentration (MIC) and characterization of antibacterial activity. The substance was thiocolchicoside, in concentrations ranging from 0.48 to 1000 µg/mL. Low sensitivity of bacterial strains to the myorelaxant was observed, obtaining an MIC of 500 µg/mL for E. coli and 1000 µg/mL for P. aeruginosa, the only strains sensitive to the compound. In the antibacterial activity characterization test, thiocolchicoside showed bacteriostatic action. The conclusions this research indicate the need to studies are needed on its action in comparison with other microorganisms, such as other bacterial species, fungi and protozoa, in order to evaluate its effect on other pathogenic organisms.